与新冠病毒肺炎及新冠病毒疫苗接种相关的心肌炎
Myocarditis Related to COVID-19 and SARS-CoV-2 Vaccination.
作者信息
Molina-Ramos Ana I, Gómez-Moyano Elisabeth, Rodríguez-Capitán Jorge, Angullo-Gómez María, Gallardo-Jiménez Patricia, Pérez de Pedro Iván, Valiente de Santis Lucía, Pérez-Villardón Beatriz, Piñero-Uribe Isabel, Mora-Robles Javier, Becerra-Muñoz Víctor Manuel, Jiménez-Navarro Manuel
机构信息
Centro de Investigación en Red de Enfermedades Cardiovasculares (CIBERCV), Cardiology Department, Hospital Universitario Virgen de la Victoria, 29010 Málaga, Spain.
IBIMA-Plataforma BIONAND, Universidad de Málaga, 29590 Málaga, Spain.
出版信息
J Clin Med. 2022 Nov 26;11(23):6999. doi: 10.3390/jcm11236999.
The coronavirus disease of 2019 (COVID-19) has been a cause of significant morbidity and mortality worldwide. Among the short- and long-term consequences of COVID-19, myocarditis is a disease to be taken into consideration. Myocarditis, in general, is related to a poor prognosis. However, the epidemiology and prognosis of myocarditis related to COVID-19 are currently unknown. While vaccination against COVID-19 is of great benefit at a public health level, the risk of myocarditis should be considered in the context of the global benefits of vaccination. In this narrative review, we will summarize the etiopathogenic bases, the epidemiology, the clinical manifestations, the course, diagnosis, prognosis, and the treatment of myocarditis related to SARS-CoV-2, as well as myocarditis secondary to mRNA vaccines.
2019年冠状病毒病（COVID-19）已成为全球重大发病和死亡原因。在COVID-19的短期和长期后果中，心肌炎是一种需要考虑的疾病。一般来说，心肌炎与不良预后相关。然而，与COVID-19相关的心肌炎的流行病学和预后目前尚不清楚。虽然COVID-19疫苗接种在公共卫生层面有很大益处，但应在疫苗接种的全球益处背景下考虑心肌炎风险。在这篇叙述性综述中，我们将总结与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）相关的心肌炎以及信使核糖核酸（mRNA）疫苗继发的心肌炎的病因基础、流行病学、临床表现、病程、诊断、预后和治疗。
Zotero 插件